David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on Biosyent. The associated price target was raised to C$13.50.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Martin PhD’s rating is based on several compelling factors. Firstly, BioSyent’s recent financial performance has exceeded expectations, particularly in the third quarter of 2025, where the company reported results that surpassed market estimates. This strong performance is largely attributed to the continued success of their flagship product, Feramax, which remains a significant revenue driver.
Additionally, the company’s legacy insecticide business has also contributed positively, providing a diversified income stream that strengthens BioSyent’s overall financial position. These factors combined suggest a promising growth trajectory for the company, justifying the Buy rating given by David Martin PhD.
RX’s price has also changed slightly for the past six months – from C$11.700 to C$10.760, which is a -8.03% drop .